Page 19 - காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால Today - Breaking & Trending Today

BioNTech SE: Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared


BioNTech SE: Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2 infection
Latest data analysis finds unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19
Findings represent the most comprehensive real-world evidence to date demonstrating the effectiveness of a COVID-19 vaccine
Data are of global importance to other countries as vaccination campaigns continue worldwide
JERUSALEM, NEW YORK and MAINZ, GERMANY, March 11, 2021 - The Israel Ministry of Health(Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public heal ....

Israel General , United States , United Kingdom , Sylke Maas , Luis Jodar , Chuck Triano , Amy Rose , Ugur Sahin , Fosun Pharma , Israel Ministry Of Health Director , Israel Ministry Of Health , Bayer Animal Health , European Union , Centers For Disease , World Health Organization , Drug Administration , Exchange Commission , Israel Ministry Of Health Nasdaq , Israel Moh Vaccination Program , Roche Group , Vaccine Administration Under Emergency Use Authorization , Israel Ministry , Israel Moh , Professor Yeheskel Levy , Senior Vice President , Chief Medical Officer ,

Investegate |BioNTech SE Announcements | BioNTech SE: Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared


BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program. These new data build upon and confirm previously released data from the MoH demonstrating the vaccine’s effectiveness in preventing symptomatic SARS-CoV-2 infections, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. The latest analysis from the MoH proves that two weeks after the second vaccine dose protection is even stronger – vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death. This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization (WHO) dec ....

Israel General , United States , United Kingdom , Sylke Maas , Luis Jodar , Chuck Triano , Amy Rose , Ugur Sahin , Fosun Pharma , Israel Ministry Of Health Director , Israel Ministry Of Health , Bayer Animal Health , Pfizer Inc , European Union , Israel Ministry Of Health Mo , Centers For Disease , Drug Administration , World Health Organization , Exchange Commission , Israel Moh Vaccination Program , Roche Group , Vaccine Administration Under Emergency Use Authorization , Real World Evidence Confirms High Effectiveness , Profound Public Health Impact , Vaccination One Year After Pandemic , Israel Ministry ,

Pfizer Inc.: Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared


Pfizer Inc.: Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2 infection
Latest data analysis finds unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19
Findings represent the most comprehensive real-world evidence to date demonstrating the effectiveness of a COVID-19 vaccine
Data are of global importance to other countries as vaccination campaigns continue worldwide
The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact ....

United States , United Kingdom , Sylke Maas , Luis Jodar , Chuck Triano , Amy Rose , Ugur Sahin , Fosun Pharma , Israel Ministry Of Health Director , Israel Ministry Of Health , Bayer Animal Health , Pfizer Inc , European Union , Israel Ministry Of Health Mo , Centers For Disease , Drug Administration , World Health Organization , Exchange Commission , Israel Moh Vaccination Program , Roche Group , Vaccine Administration Under Emergency Use Authorization , Israel Ministry , Israel Moh , Professor Yeheskel Levy , Senior Vice President Chief Medical Officer , Marketing Authorization Holder ,

Valneva : and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate


Pfizer Forward-Looking Statements
The information contained in this release is as of March 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. 
This release contains forward-looking information about a Lyme disease vaccine candidate, VLA15, and a collaboration between Pfizer and Valneva for VLA15, including their potential benefits and a potential phase 3 start, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorabl ....

United States , New York , Kathrin Jansen , Bryan Dunn , Juan Carlos Jaramillo , Jerica Pitts , Us Centers For Disease , Drug Administration , Exchange Commission , Pfizer Inc , Head Of Pfizer Vaccine Research , Investor Relations Corporate Communications , Senior Vice President , Pfizer Vaccine Research , Carlos Jaramillo , Chief Medical Officer , North America , Fast Track , Primary Endpoint , Booster Phase , Disease Control , Breakthroughs That Change Patient , Annual Report , Looking Information , Factors That May Affect Future , Lyme Report ,